Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2016-05

AUTHORS

J. Duerinck, S. Du Four, F. Vandervorst, N. D’Haene, M. Le Mercier, A. Michotte, A. M. Van Binst, H. Everaert, I. Salmon, F. Bouttens, V. Verschaeve, B. Neyns

ABSTRACT

We conducted a randomized, non-comparative, multi center, phase II clinical trial in order to investigate the efficacy of axitinib, an oral small molecule tyrosine kinase inhibitor with high affinity and specificity for the vascular endothelial growth factor receptors, in patients with recurrent glioblastoma following prior treatment with radiation and temozolomide. Forty-four patients were randomly assigned to receive treatment with axitinib (5 mg BID starting dose; N = 22) or "physicians best alternative choice of therapy" that consisted of bevacizumab (N = 20) or lomustine (N = 2). Six-month progression-free survival served as the primary endpoint. The estimated 6-month progression-free survival rate was 34 % (95 % CI 14-54) for patients treated with axitinib and 28 % (95 % CI 8-48) with best alternative treatment; median overall survival was 29 and 17 weeks, respectively. Objective responses according to RANO criteria were documented in 28 % of patients treated with axitinib and 23 % of patients treated with best alternative therapy. A decrease in maximal uptake of 18F-fluoro-ethyL-tyrosine (18F-FET) by the glioblastoma on PET imaging was documented in 85 % of patients at the time of response on axitinib. Corticosteroid treatment could be stopped in four and tapered in seven out of the 15 patients who were treated with steroids at baseline in the axitinib cohort. Most frequent axitinib related grade ≥3 adverse events consisted of fatigue (9 %), diarrhea (9 %), and oral hyperesthesia (4.5 %). We conclude that axitinib has single-agent clinical activity and a manageable toxicity profile in patients with recurrent glioblastoma. More... »

PAGES

147-155

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11060-016-2092-2

DOI

http://dx.doi.org/10.1007/s11060-016-2092-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1020341782

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/26935577


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiogenesis Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents, Alkylating", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bevacizumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Brain Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorodeoxyglucose F18", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glioblastoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Imidazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Indazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lomustine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Positron-Emission Tomography", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein-Tyrosine Kinases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiopharmaceuticals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Steroids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Universitair Ziekenhuis Brussel", 
          "id": "https://www.grid.ac/institutes/grid.411326.3", 
          "name": [
            "Department of Medical Oncology, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090, Brussels, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Duerinck", 
        "givenName": "J.", 
        "id": "sg:person.01217025001.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217025001.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universitair Ziekenhuis Brussel", 
          "id": "https://www.grid.ac/institutes/grid.411326.3", 
          "name": [
            "Department of Neurosurgery, Universitair Ziekenhuis Brussel, Brussels, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Du Four", 
        "givenName": "S.", 
        "id": "sg:person.01071402240.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01071402240.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universitair Ziekenhuis Brussel", 
          "id": "https://www.grid.ac/institutes/grid.411326.3", 
          "name": [
            "Department of Medical Oncology, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090, Brussels, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vandervorst", 
        "givenName": "F.", 
        "id": "sg:person.0602727541.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0602727541.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universit\u00e9 Libre de Bruxelles", 
          "id": "https://www.grid.ac/institutes/grid.4989.c", 
          "name": [
            "Department of Pathology, Hopital Erasme Universit\u00e9 Libre de Bruxelles, Brussels, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "D\u2019Haene", 
        "givenName": "N.", 
        "id": "sg:person.01165076110.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165076110.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universit\u00e9 Libre de Bruxelles", 
          "id": "https://www.grid.ac/institutes/grid.4989.c", 
          "name": [
            "Department of Pathology, Hopital Erasme Universit\u00e9 Libre de Bruxelles, Brussels, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Le Mercier", 
        "givenName": "M.", 
        "id": "sg:person.01117673767.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117673767.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universitair Ziekenhuis Brussel", 
          "id": "https://www.grid.ac/institutes/grid.411326.3", 
          "name": [
            "Department of Pathology and Neurology, Universitair Ziekenhuis Brussel, Brussels, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Michotte", 
        "givenName": "A.", 
        "id": "sg:person.01006231423.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006231423.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universitair Ziekenhuis Brussel", 
          "id": "https://www.grid.ac/institutes/grid.411326.3", 
          "name": [
            "Department of Radiology, Universitair Ziekenhuis Brussel, Brussels, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Van Binst", 
        "givenName": "A. M.", 
        "id": "sg:person.0717425045.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717425045.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universitair Ziekenhuis Brussel", 
          "id": "https://www.grid.ac/institutes/grid.411326.3", 
          "name": [
            "Department of Nuclear Medicine, Universitair Ziekenhuis Brussel, Brussels, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Everaert", 
        "givenName": "H.", 
        "id": "sg:person.0756522502.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756522502.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universit\u00e9 Libre de Bruxelles", 
          "id": "https://www.grid.ac/institutes/grid.4989.c", 
          "name": [
            "Department of Pathology, Hopital Erasme Universit\u00e9 Libre de Bruxelles, Brussels, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Salmon", 
        "givenName": "I.", 
        "id": "sg:person.0772641113.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0772641113.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Medical Radiation Oncology, AZ Sint-Lucas Gent, Ghent, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bouttens", 
        "givenName": "F.", 
        "id": "sg:person.01261545100.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261545100.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Grand Charleroi Hospital", 
          "id": "https://www.grid.ac/institutes/grid.490655.b", 
          "name": [
            "Department of Medical Oncology, GHDC, Charleroi, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Verschaeve", 
        "givenName": "V.", 
        "id": "sg:person.01261121601.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261121601.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universitair Ziekenhuis Brussel", 
          "id": "https://www.grid.ac/institutes/grid.411326.3", 
          "name": [
            "Department of Medical Oncology, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090, Brussels, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Neyns", 
        "givenName": "B.", 
        "id": "sg:person.0576756400.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0576756400.18"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s1470-2045(09)70025-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002463620"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.16.3055", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010751135"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/nar/28.8.e32", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014093221"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-03-3852", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014286674"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0138245", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016533010"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00415-014-7633-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017955987", 
          "https://doi.org/10.1007/s00415-014-7633-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.47.2464", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028825119"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jmoldx.2014.09.004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029660778"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/bib/bbs017", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029766327"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-014-1612-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031602922", 
          "https://doi.org/10.1007/s11060-014-1612-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.m112.437962", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033438159"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/his.12461", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033772047"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2353/jmoldx.2006.050135", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033835302"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cmr.0b013e3283538293", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034500863"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cmr.0b013e3283538293", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034500863"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3389/fonc.2013.00104", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041020531"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.19.8721", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042965400"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1541-7786.mcr-06-0085", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043369568"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00401-014-1352-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045389245", 
          "https://doi.org/10.1007/s00401-014-1352-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00401-014-1352-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045389245", 
          "https://doi.org/10.1007/s00401-014-1352-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-06-1010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045960685"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cad.0000000000000033", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046031570"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cad.0000000000000033", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046031570"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1215/15228517-2007-062", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046098276"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00259-012-2251-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048801315", 
          "https://doi.org/10.1007/s00259-012-2251-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-010-0402-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050941168", 
          "https://doi.org/10.1007/s11060-010-0402-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2014.55.9575", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052929928"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1582-4934.2007.00153.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053602750"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/2162402x.2014.998107", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1058420410"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.8.2572", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074549881"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.6004/jnccn.2011.0038", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1078376979"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.6004/jnccn.2011.0038", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1078376979"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-05", 
    "datePublishedReg": "2016-05-01", 
    "description": "We conducted a randomized, non-comparative, multi center, phase II clinical trial in order to investigate the efficacy of axitinib, an oral small molecule tyrosine kinase inhibitor with high affinity and specificity for the vascular endothelial growth factor receptors, in patients with recurrent glioblastoma following prior treatment with radiation and temozolomide. Forty-four patients were randomly assigned to receive treatment with axitinib (5\u00a0mg BID starting dose; N\u00a0=\u00a022) or \"physicians best alternative choice of therapy\" that consisted of bevacizumab (N\u00a0=\u00a020) or lomustine (N\u00a0=\u00a02). Six-month progression-free survival served as the primary endpoint. The estimated 6-month progression-free survival rate was 34\u00a0% (95\u00a0% CI 14-54) for patients treated with axitinib and 28\u00a0% (95\u00a0% CI 8-48) with best alternative treatment; median overall survival was 29 and 17\u00a0weeks, respectively. Objective responses according to RANO criteria were documented in 28\u00a0% of patients treated with axitinib and 23\u00a0% of patients treated with best alternative therapy. A decrease in maximal uptake of 18F-fluoro-ethyL-tyrosine (18F-FET) by the glioblastoma on PET imaging was documented in 85\u00a0% of patients at the time of response on axitinib. Corticosteroid treatment could be stopped in four and tapered in seven out of the 15 patients who were treated with steroids at baseline in the axitinib cohort. Most frequent axitinib related grade \u22653 adverse events consisted of fatigue (9\u00a0%), diarrhea (9\u00a0%), and oral hyperesthesia (4.5\u00a0%). We conclude that axitinib has single-agent clinical activity and a manageable toxicity profile in patients with recurrent glioblastoma.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s11060-016-2092-2", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094205", 
        "issn": [
          "0167-594X", 
          "1573-7373"
        ], 
        "name": "Journal of Neuro-Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "128"
      }
    ], 
    "name": "Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma", 
    "pagination": "147-155", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "60ec22ebee407c445ed6e2cbe8d51191ffd58b0039adf7ec36a6114352603912"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "26935577"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309335"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11060-016-2092-2"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1020341782"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11060-016-2092-2", 
      "https://app.dimensions.ai/details/publication/pub.1020341782"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T14:14", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8660_00000531.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs11060-016-2092-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11060-016-2092-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11060-016-2092-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11060-016-2092-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11060-016-2092-2'


 

This table displays all metadata directly associated to this object as RDF triples.

343 TRIPLES      21 PREDICATES      81 URIs      45 LITERALS      33 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11060-016-2092-2 schema:about N11dabf16e570493c8dadf3771f6702c7
2 N1d1642467d94473898fa3715f3efaf78
3 N1f9e85bcf085404585b8b15774b26317
4 N20322865f8494d498e886ee968df6b43
5 N2e161da1e11f445aba88bdca71e9494a
6 N42ff44b1cced49cbbe92369257516331
7 N47d9559686594de499e8686a67c0f829
8 N6acd2c4e252a475fa65e6f019bad5acc
9 N73bf704c578c406fa7b94186ddd47df9
10 N7b9585f363ab471b9f94eb52a00e7813
11 N7ff1dc45c60442f5bcb5d0d31e3c762f
12 N817968ae313d4dcbb0a981d787ee7def
13 N849fda08952440658d48f450025c8339
14 N84fb335e03b94febbfdcfdc1bcb0d650
15 N8f7fd05b6fba4715867f98282e04885f
16 N9516974764944dd1a032709233e20d54
17 Na24070d73d2c41c3af0039e60a01e1ef
18 Na2ddc032acef41469db3627c86f72b45
19 Nb284500e0e7f4c87ba6a4e67d0b3d000
20 Nb5b8c7fb1a35414c84adb169f46505a9
21 Nb72df672bc874c239357e04dd3cce381
22 Ncd5e6a3cdc3e4fbeb879b4f96592161e
23 Ncdab1c5e57fa44d49a19c385fe3ef86d
24 Nea693926374b4131a9a034de73d9dd4a
25 anzsrc-for:11
26 anzsrc-for:1103
27 schema:author Ne047572858dd41548c6e6e2e2444fec2
28 schema:citation sg:pub.10.1007/s00259-012-2251-4
29 sg:pub.10.1007/s00401-014-1352-5
30 sg:pub.10.1007/s00415-014-7633-z
31 sg:pub.10.1007/s11060-010-0402-7
32 sg:pub.10.1007/s11060-014-1612-1
33 https://doi.org/10.1016/j.jmoldx.2014.09.004
34 https://doi.org/10.1016/s1470-2045(09)70025-7
35 https://doi.org/10.1074/jbc.m112.437962
36 https://doi.org/10.1080/2162402x.2014.998107
37 https://doi.org/10.1093/bib/bbs017
38 https://doi.org/10.1093/nar/28.8.e32
39 https://doi.org/10.1097/cad.0000000000000033
40 https://doi.org/10.1097/cmr.0b013e3283538293
41 https://doi.org/10.1111/his.12461
42 https://doi.org/10.1111/j.1582-4934.2007.00153.x
43 https://doi.org/10.1158/0008-5472.can-03-3852
44 https://doi.org/10.1158/0008-5472.can-06-1010
45 https://doi.org/10.1158/1541-7786.mcr-06-0085
46 https://doi.org/10.1200/jco.1999.17.8.2572
47 https://doi.org/10.1200/jco.2008.16.3055
48 https://doi.org/10.1200/jco.2008.19.8721
49 https://doi.org/10.1200/jco.2012.47.2464
50 https://doi.org/10.1200/jco.2014.55.9575
51 https://doi.org/10.1215/15228517-2007-062
52 https://doi.org/10.1371/journal.pone.0138245
53 https://doi.org/10.2353/jmoldx.2006.050135
54 https://doi.org/10.3389/fonc.2013.00104
55 https://doi.org/10.6004/jnccn.2011.0038
56 schema:datePublished 2016-05
57 schema:datePublishedReg 2016-05-01
58 schema:description We conducted a randomized, non-comparative, multi center, phase II clinical trial in order to investigate the efficacy of axitinib, an oral small molecule tyrosine kinase inhibitor with high affinity and specificity for the vascular endothelial growth factor receptors, in patients with recurrent glioblastoma following prior treatment with radiation and temozolomide. Forty-four patients were randomly assigned to receive treatment with axitinib (5 mg BID starting dose; N = 22) or "physicians best alternative choice of therapy" that consisted of bevacizumab (N = 20) or lomustine (N = 2). Six-month progression-free survival served as the primary endpoint. The estimated 6-month progression-free survival rate was 34 % (95 % CI 14-54) for patients treated with axitinib and 28 % (95 % CI 8-48) with best alternative treatment; median overall survival was 29 and 17 weeks, respectively. Objective responses according to RANO criteria were documented in 28 % of patients treated with axitinib and 23 % of patients treated with best alternative therapy. A decrease in maximal uptake of 18F-fluoro-ethyL-tyrosine (18F-FET) by the glioblastoma on PET imaging was documented in 85 % of patients at the time of response on axitinib. Corticosteroid treatment could be stopped in four and tapered in seven out of the 15 patients who were treated with steroids at baseline in the axitinib cohort. Most frequent axitinib related grade ≥3 adverse events consisted of fatigue (9 %), diarrhea (9 %), and oral hyperesthesia (4.5 %). We conclude that axitinib has single-agent clinical activity and a manageable toxicity profile in patients with recurrent glioblastoma.
59 schema:genre research_article
60 schema:inLanguage en
61 schema:isAccessibleForFree false
62 schema:isPartOf N195e039fa7244b18b47f0b09954cff10
63 Nce4816da46624e449ce82c737e53650e
64 sg:journal.1094205
65 schema:name Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma
66 schema:pagination 147-155
67 schema:productId N17bec7a5c1574746b51bf4aff2c68238
68 N1cf1cc74b2c641709827e5d14ecd352e
69 N2d514636d50f4f229f04d2745c993e97
70 N82e2d03dd5b04a0394978657c38f28fc
71 N931f426ad8b0498ea0217c007be04ea5
72 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020341782
73 https://doi.org/10.1007/s11060-016-2092-2
74 schema:sdDatePublished 2019-04-10T14:14
75 schema:sdLicense https://scigraph.springernature.com/explorer/license/
76 schema:sdPublisher N09bba4bee9364b7f99814293e9e055ea
77 schema:url http://link.springer.com/10.1007%2Fs11060-016-2092-2
78 sgo:license sg:explorer/license/
79 sgo:sdDataset articles
80 rdf:type schema:ScholarlyArticle
81 N09bba4bee9364b7f99814293e9e055ea schema:name Springer Nature - SN SciGraph project
82 rdf:type schema:Organization
83 N11dabf16e570493c8dadf3771f6702c7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Female
85 rdf:type schema:DefinedTerm
86 N17bec7a5c1574746b51bf4aff2c68238 schema:name dimensions_id
87 schema:value pub.1020341782
88 rdf:type schema:PropertyValue
89 N195e039fa7244b18b47f0b09954cff10 schema:issueNumber 1
90 rdf:type schema:PublicationIssue
91 N1cf1cc74b2c641709827e5d14ecd352e schema:name doi
92 schema:value 10.1007/s11060-016-2092-2
93 rdf:type schema:PropertyValue
94 N1d1642467d94473898fa3715f3efaf78 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Humans
96 rdf:type schema:DefinedTerm
97 N1f9e85bcf085404585b8b15774b26317 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Protein-Tyrosine Kinases
99 rdf:type schema:DefinedTerm
100 N20322865f8494d498e886ee968df6b43 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Treatment Outcome
102 rdf:type schema:DefinedTerm
103 N27439af116f2471d88590d425f601789 rdf:first sg:person.01165076110.00
104 rdf:rest N962847901bb84d368a2d63fed776c7e4
105 N2d1bcf3b41224cdfa2b6c8a98dde90f4 rdf:first sg:person.0576756400.18
106 rdf:rest rdf:nil
107 N2d514636d50f4f229f04d2745c993e97 schema:name readcube_id
108 schema:value 60ec22ebee407c445ed6e2cbe8d51191ffd58b0039adf7ec36a6114352603912
109 rdf:type schema:PropertyValue
110 N2e161da1e11f445aba88bdca71e9494a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Brain Neoplasms
112 rdf:type schema:DefinedTerm
113 N2fb78ce445e14feb97afe72040480192 rdf:first sg:person.0756522502.33
114 rdf:rest N7b0be0e01adf44eaa587c94504c942d2
115 N42ff44b1cced49cbbe92369257516331 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Radiopharmaceuticals
117 rdf:type schema:DefinedTerm
118 N47d9559686594de499e8686a67c0f829 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Middle Aged
120 rdf:type schema:DefinedTerm
121 N58fed528fa7c44538701f2b582b8b096 rdf:first sg:person.01261545100.39
122 rdf:rest N5b500b46356a447eabcbe58e3f43ac3c
123 N5b500b46356a447eabcbe58e3f43ac3c rdf:first sg:person.01261121601.82
124 rdf:rest N2d1bcf3b41224cdfa2b6c8a98dde90f4
125 N6acd2c4e252a475fa65e6f019bad5acc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Lomustine
127 rdf:type schema:DefinedTerm
128 N73bf704c578c406fa7b94186ddd47df9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Imidazoles
130 rdf:type schema:DefinedTerm
131 N7b0be0e01adf44eaa587c94504c942d2 rdf:first sg:person.0772641113.37
132 rdf:rest N58fed528fa7c44538701f2b582b8b096
133 N7b9585f363ab471b9f94eb52a00e7813 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Glioblastoma
135 rdf:type schema:DefinedTerm
136 N7ff1dc45c60442f5bcb5d0d31e3c762f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Positron-Emission Tomography
138 rdf:type schema:DefinedTerm
139 N817968ae313d4dcbb0a981d787ee7def schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Bevacizumab
141 rdf:type schema:DefinedTerm
142 N82e2d03dd5b04a0394978657c38f28fc schema:name nlm_unique_id
143 schema:value 8309335
144 rdf:type schema:PropertyValue
145 N849fda08952440658d48f450025c8339 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Male
147 rdf:type schema:DefinedTerm
148 N84fb335e03b94febbfdcfdc1bcb0d650 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Fluorodeoxyglucose F18
150 rdf:type schema:DefinedTerm
151 N8f7fd05b6fba4715867f98282e04885f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Disease-Free Survival
153 rdf:type schema:DefinedTerm
154 N931f426ad8b0498ea0217c007be04ea5 schema:name pubmed_id
155 schema:value 26935577
156 rdf:type schema:PropertyValue
157 N9516974764944dd1a032709233e20d54 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Neoplasm Recurrence, Local
159 rdf:type schema:DefinedTerm
160 N962847901bb84d368a2d63fed776c7e4 rdf:first sg:person.01117673767.30
161 rdf:rest Nc0c429c57da24391bb26326941567262
162 N9e99f417d0d148df8b1377159ab25efe rdf:first sg:person.0602727541.19
163 rdf:rest N27439af116f2471d88590d425f601789
164 Na24070d73d2c41c3af0039e60a01e1ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Young Adult
166 rdf:type schema:DefinedTerm
167 Na2ddc032acef41469db3627c86f72b45 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Protein Kinase Inhibitors
169 rdf:type schema:DefinedTerm
170 Nb284500e0e7f4c87ba6a4e67d0b3d000 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Steroids
172 rdf:type schema:DefinedTerm
173 Nb5b8c7fb1a35414c84adb169f46505a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Indazoles
175 rdf:type schema:DefinedTerm
176 Nb72df672bc874c239357e04dd3cce381 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Angiogenesis Inhibitors
178 rdf:type schema:DefinedTerm
179 Nbd880151031b49b480fc4d61d4e3bab4 rdf:first sg:person.01071402240.01
180 rdf:rest N9e99f417d0d148df8b1377159ab25efe
181 Nc0c429c57da24391bb26326941567262 rdf:first sg:person.01006231423.46
182 rdf:rest Nf7d1adcddbf0429cbc41b3844a3db436
183 Ncd5e6a3cdc3e4fbeb879b4f96592161e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Aged
185 rdf:type schema:DefinedTerm
186 Ncdab1c5e57fa44d49a19c385fe3ef86d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Adult
188 rdf:type schema:DefinedTerm
189 Nce4816da46624e449ce82c737e53650e schema:volumeNumber 128
190 rdf:type schema:PublicationVolume
191 Ne047572858dd41548c6e6e2e2444fec2 rdf:first sg:person.01217025001.27
192 rdf:rest Nbd880151031b49b480fc4d61d4e3bab4
193 Nea693926374b4131a9a034de73d9dd4a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Antineoplastic Agents, Alkylating
195 rdf:type schema:DefinedTerm
196 Nf7d1adcddbf0429cbc41b3844a3db436 rdf:first sg:person.0717425045.78
197 rdf:rest N2fb78ce445e14feb97afe72040480192
198 Nff553b401b074504bc4348a0e4da22f8 schema:name Department of Medical Radiation Oncology, AZ Sint-Lucas Gent, Ghent, Belgium
199 rdf:type schema:Organization
200 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
201 schema:name Medical and Health Sciences
202 rdf:type schema:DefinedTerm
203 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
204 schema:name Clinical Sciences
205 rdf:type schema:DefinedTerm
206 sg:journal.1094205 schema:issn 0167-594X
207 1573-7373
208 schema:name Journal of Neuro-Oncology
209 rdf:type schema:Periodical
210 sg:person.01006231423.46 schema:affiliation https://www.grid.ac/institutes/grid.411326.3
211 schema:familyName Michotte
212 schema:givenName A.
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006231423.46
214 rdf:type schema:Person
215 sg:person.01071402240.01 schema:affiliation https://www.grid.ac/institutes/grid.411326.3
216 schema:familyName Du Four
217 schema:givenName S.
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01071402240.01
219 rdf:type schema:Person
220 sg:person.01117673767.30 schema:affiliation https://www.grid.ac/institutes/grid.4989.c
221 schema:familyName Le Mercier
222 schema:givenName M.
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117673767.30
224 rdf:type schema:Person
225 sg:person.01165076110.00 schema:affiliation https://www.grid.ac/institutes/grid.4989.c
226 schema:familyName D’Haene
227 schema:givenName N.
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165076110.00
229 rdf:type schema:Person
230 sg:person.01217025001.27 schema:affiliation https://www.grid.ac/institutes/grid.411326.3
231 schema:familyName Duerinck
232 schema:givenName J.
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217025001.27
234 rdf:type schema:Person
235 sg:person.01261121601.82 schema:affiliation https://www.grid.ac/institutes/grid.490655.b
236 schema:familyName Verschaeve
237 schema:givenName V.
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261121601.82
239 rdf:type schema:Person
240 sg:person.01261545100.39 schema:affiliation Nff553b401b074504bc4348a0e4da22f8
241 schema:familyName Bouttens
242 schema:givenName F.
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261545100.39
244 rdf:type schema:Person
245 sg:person.0576756400.18 schema:affiliation https://www.grid.ac/institutes/grid.411326.3
246 schema:familyName Neyns
247 schema:givenName B.
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0576756400.18
249 rdf:type schema:Person
250 sg:person.0602727541.19 schema:affiliation https://www.grid.ac/institutes/grid.411326.3
251 schema:familyName Vandervorst
252 schema:givenName F.
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0602727541.19
254 rdf:type schema:Person
255 sg:person.0717425045.78 schema:affiliation https://www.grid.ac/institutes/grid.411326.3
256 schema:familyName Van Binst
257 schema:givenName A. M.
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717425045.78
259 rdf:type schema:Person
260 sg:person.0756522502.33 schema:affiliation https://www.grid.ac/institutes/grid.411326.3
261 schema:familyName Everaert
262 schema:givenName H.
263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756522502.33
264 rdf:type schema:Person
265 sg:person.0772641113.37 schema:affiliation https://www.grid.ac/institutes/grid.4989.c
266 schema:familyName Salmon
267 schema:givenName I.
268 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0772641113.37
269 rdf:type schema:Person
270 sg:pub.10.1007/s00259-012-2251-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048801315
271 https://doi.org/10.1007/s00259-012-2251-4
272 rdf:type schema:CreativeWork
273 sg:pub.10.1007/s00401-014-1352-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045389245
274 https://doi.org/10.1007/s00401-014-1352-5
275 rdf:type schema:CreativeWork
276 sg:pub.10.1007/s00415-014-7633-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1017955987
277 https://doi.org/10.1007/s00415-014-7633-z
278 rdf:type schema:CreativeWork
279 sg:pub.10.1007/s11060-010-0402-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050941168
280 https://doi.org/10.1007/s11060-010-0402-7
281 rdf:type schema:CreativeWork
282 sg:pub.10.1007/s11060-014-1612-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031602922
283 https://doi.org/10.1007/s11060-014-1612-1
284 rdf:type schema:CreativeWork
285 https://doi.org/10.1016/j.jmoldx.2014.09.004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029660778
286 rdf:type schema:CreativeWork
287 https://doi.org/10.1016/s1470-2045(09)70025-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002463620
288 rdf:type schema:CreativeWork
289 https://doi.org/10.1074/jbc.m112.437962 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033438159
290 rdf:type schema:CreativeWork
291 https://doi.org/10.1080/2162402x.2014.998107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1058420410
292 rdf:type schema:CreativeWork
293 https://doi.org/10.1093/bib/bbs017 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029766327
294 rdf:type schema:CreativeWork
295 https://doi.org/10.1093/nar/28.8.e32 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014093221
296 rdf:type schema:CreativeWork
297 https://doi.org/10.1097/cad.0000000000000033 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046031570
298 rdf:type schema:CreativeWork
299 https://doi.org/10.1097/cmr.0b013e3283538293 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034500863
300 rdf:type schema:CreativeWork
301 https://doi.org/10.1111/his.12461 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033772047
302 rdf:type schema:CreativeWork
303 https://doi.org/10.1111/j.1582-4934.2007.00153.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1053602750
304 rdf:type schema:CreativeWork
305 https://doi.org/10.1158/0008-5472.can-03-3852 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014286674
306 rdf:type schema:CreativeWork
307 https://doi.org/10.1158/0008-5472.can-06-1010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045960685
308 rdf:type schema:CreativeWork
309 https://doi.org/10.1158/1541-7786.mcr-06-0085 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043369568
310 rdf:type schema:CreativeWork
311 https://doi.org/10.1200/jco.1999.17.8.2572 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074549881
312 rdf:type schema:CreativeWork
313 https://doi.org/10.1200/jco.2008.16.3055 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010751135
314 rdf:type schema:CreativeWork
315 https://doi.org/10.1200/jco.2008.19.8721 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042965400
316 rdf:type schema:CreativeWork
317 https://doi.org/10.1200/jco.2012.47.2464 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028825119
318 rdf:type schema:CreativeWork
319 https://doi.org/10.1200/jco.2014.55.9575 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052929928
320 rdf:type schema:CreativeWork
321 https://doi.org/10.1215/15228517-2007-062 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046098276
322 rdf:type schema:CreativeWork
323 https://doi.org/10.1371/journal.pone.0138245 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016533010
324 rdf:type schema:CreativeWork
325 https://doi.org/10.2353/jmoldx.2006.050135 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033835302
326 rdf:type schema:CreativeWork
327 https://doi.org/10.3389/fonc.2013.00104 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041020531
328 rdf:type schema:CreativeWork
329 https://doi.org/10.6004/jnccn.2011.0038 schema:sameAs https://app.dimensions.ai/details/publication/pub.1078376979
330 rdf:type schema:CreativeWork
331 https://www.grid.ac/institutes/grid.411326.3 schema:alternateName Universitair Ziekenhuis Brussel
332 schema:name Department of Medical Oncology, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090, Brussels, Belgium
333 Department of Neurosurgery, Universitair Ziekenhuis Brussel, Brussels, Belgium
334 Department of Nuclear Medicine, Universitair Ziekenhuis Brussel, Brussels, Belgium
335 Department of Pathology and Neurology, Universitair Ziekenhuis Brussel, Brussels, Belgium
336 Department of Radiology, Universitair Ziekenhuis Brussel, Brussels, Belgium
337 rdf:type schema:Organization
338 https://www.grid.ac/institutes/grid.490655.b schema:alternateName Grand Charleroi Hospital
339 schema:name Department of Medical Oncology, GHDC, Charleroi, Belgium
340 rdf:type schema:Organization
341 https://www.grid.ac/institutes/grid.4989.c schema:alternateName Université Libre de Bruxelles
342 schema:name Department of Pathology, Hopital Erasme Université Libre de Bruxelles, Brussels, Belgium
343 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...